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Abstract This study aims to retrospectively analyze the
clinical characteristics, treatments, and prognosis of aggres-
sive peripheral T cell lymphoma (PTCL) patients with a
lymphoma-associated hemophagocytosis syndrome
(LAHS). We compared the clinical features and the overall
survival (OS) rates of 159 PTCL patients with and without
LAHS as well as the treatment outcomes of these patients
with CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisone) or intensive chemotherapy regimens. We
observed that in 23 % (36/159) patients PTCL was associ-
ated with LAHS. Different subtypes of PTCL in LAHS
patients were diagnosed and peripheral T cell lymphoma,
not otherwise specified (PTCL-NOS) was the main subtype
(78 %). The median survival rates of the LAHS and non-
LAHS groups were 3 and 16 months, respectively. The
elevated rates of serum β2-microglobulin, ferritin, fasting
triglycerides, and hypofibrinogen levels were higher in the
LAHS group, so were bone marrow involvement, liver
dysfunction, hepatosplenomegaly, and B symptoms. Three
patients who were treated with a plasma exchange had a
longer survival time. There was no statistically significant
difference in the OS rates between the intensive chemother-
apy and CHOP regimen groups (P>0.05). PTCL patients
with LAHS had a poorer prognosis. Awareness of the clin-
ical symptoms and laboratory findings are crucial in order to
diagnose LAHS in an early stage and repeated biopsies of
multiple bone marrows from different locations in those
patients without enlargement of superficial lymph nodes
are necessary to improve the diagnosis. Intensive chemo-
therapy due to its severe toxicity was not obviously advan-
tageous for the OS rate compared to the CHOP regimen.
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Introduction
Aggressive peripheral T cell lymphomas (PTCLs) account
for about 7–10 % of non-Hodgkin's lymphomas (NHLs) in
Western countries, compared to 20–30 % NHLs in East Asia
[1, 2]. They are usually characterized by a diffuse disease
process in 68 %, systemic symptoms in nearly half (45 %),
bone marrow involvement (BMI) in a quarter (26 %), and
extra nodal diseases in a third (37 %) of the patients [3].
Hemophagocytic lymphohistiocytosis (HLH) is an occa-
sional but severe complication of PTCL in which T cells
induce the uncontrolled activation of phagocytosing macro-
phages, leading to the lymphoma-associated hemophagocy-
tosis syndrome (LAHS) with a high fatality rate [3, 4], and
no particular mode of therapy has been satisfactory enough
yet for the treatment of PTCL complicated with the LAHS.
HLH is a potentially fatal hyperinflammatory condition. It
includes genetic (primary) HLH, which is due to mutations
in genes important for the cytolytic secretory pathway and
causes perforin and granzymes to induce apoptosis in target
cells and acquired (secondary) HLH, which occurs as a
secondary disorder in association with severe infections,
malignancies, rheumatologic disorders, and some metabolic
diseases [5]. In non-immunocompromised patients, the main
malignancy to be found associated with HLH is T cell
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lymphoma, leading to the LAHS [6]. However, reports of
the clinical features of the LAHS are relatively rare, and
only some case reports and author's experiences are avail-
able [7, 8]. Thus, we performed a retrospective analysis of
clinical features from a large series of patients diagnosed
with PTCLs by the criteria of the World Health Organization
(WHO) Classification and analyzed the clinical features of
LAHS, including the relationship between LAHS and some
sub-types of PTCL, the clinical manifestations, some labo-
ratory findings, and overall survival (OS) rates of different
treatments in order to elucidate the clinical characteristics,
treatments, and prognosis of LAHS patients.
Materials and methods
Patients
We consecutively reviewed 159 patients diagnosed with
PTCL and who were hospitalized between January 2005
and December 2011 in the Zhejiang University First Affil-
iated Hospital of the Medical School. All diagnoses were
confirmed by histopathological hematoxylin and eosin
staining as well as determination of the immunophenotypes
according to the WHO Classification 2008 [9]. Complete
clinical profiles of all 159 patients who received chemother-
apy and finished the follow-up were obtained. Clinical stag-
ing and diagnostic methods included a clinical history and
physical examination, chest, abdominal, and pelvic comput-
ed tomography (CT) scans, full-digital full-body color
Doppler ultrasonic diagnostic analyzer examinations as well
as bone marrow aspirate and biopsy investigations. Clinical
data collected for each patient included lactate dehydroge-
nase (LDH) and β2-microglobulin (β2-MG) levels, immu-
noglobulin (IG), blood biochemical functions, liver
function, blood routine, coagulation functions, tumor
markers, ferritin, bone marrow smear, and chemotherapy
regimens. We analyzed the differences in laboratory find-
ings and OS rates between PTCL patients with or without
LAHS. In addition, we also compared the outcome of the
patients who received CHOP or intensive chemotherapy
regimens in LAHS patients. Informed consents were
obtained from all patients before the collection of patients'
information and serum samples for analyses.
Immunohistochemical staining
Sections of all patients were stained with T cell (CD2, CD3,
and CD45) and B cell (CD20 and CD79a) markers by using
mouse monoclonal antibodies, and disease specificity was
confirmed in case that positive staining was observed only
with one or more T cell-specific markers without any posi-
tive B cell-specific marker staining. Moreover, CD30 and
anaplastic leukemia kinase-1 immunostaining were further
used for the differential diagnosis of systemic anaplastic
large cell lymphoma, and CD56, CD57, TIA-1, and gran-
zyme B were used as marker for NK/T cell lymphoma
diagnosis.
Diagnostic criteria for LAHS
The diagnostic criteria for LAHS are listed in Table 1 [10].
Clinical staging
Disease grades were evaluated according to the Ann Arbor
Staging System [11] and performance status evaluation
based on the Eastern Cooperative Oncology Group scale
(0–4) [12]. The patients' international prognostic index
[13] scores were determined and used in the survival rate
analyses.
Treatment
Chemotherapy regimens including CHOP (cyclophospha-
mide 750 mg/m2, day 1, epirubicin 60 mg/m2 day 1, vin-
cristine 1.4 mg/m2 day 1, and prednisolone 100 mg days 1–
5) or CHOP-like regimens (idamycin (8 mg/m2 day 1),
mitoxantrone (8 mg/m2 day 1), or liposomal doxorubicin
(40 mg/m2 day 1) substituting for epirubicin) were
employed. Intensive chemotherapies included ECHOP
(CHOP with etoposide 100 mgdays 1–3), CHOP with
Ara-C (cytosine arabinoside 200 mg days 1–7), MINE
(mitoxantrone 8 mg/m2 days 1–3, isophosphamide 2.0 g
days 1–3, mesna 500 mg/m2 days 1–3 4 h after each iso-
phosphamide, etoposide 100 mg days 1–3), ESHAP (etopo-
side 40 mg/m2 days 1–4, solumedrol 250–500 mg days 1–5,
Table 1 Diagnostic criteria for LAHS
The primary disease diagnosed as lymphoma
At least five of the following eight criteria mentioned were required
Fever
Splenomegaly
Cytopenia ≥2 cell lines








Decreased or absent NK cell activity
Hemophagocytosis in bone marrow, CSF, or lymph nodes
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Ara-C 2 g/m2 day 5, platinol 25 mg/m2 days 1–4), DHAP
(cisplatin 100 mg/m2 day 1, dexamethasone 40 mg days 1–
4, cytarabine 2.0/m2 q12h day 2), and hyper CVAD (cyclo-
phosphamide 300 mg/m2 q12h days 1–3, doxorubicin
50 mg/m2 day 4, vincristine 2 mg days 4 and 11, dexameth-
asone 40 mg days 1–4 and 11–14).
Statistics
OS rates were calculated beginning from the date of diag-
nosis to death or the last follow-up date. Survival curves
were analyzed by the Kaplan–Meier method and log-rank
test was used for comparisons between individual clinical
features and survival. χ2 test was used to compare the
clinical and laboratory data of T cell lymphomas with and
without LAHS. Statistical significance was defined as a P-
value <0.05. All data were processed with the Statistical
Package for the Social Sciences 16 software.
Results
Patient characteristics
Thirty-six of the 159 PTCL patients were diagnosed with
LAHS. In the LAHS group, 28 (78 %) patients had periph-
eral T cell lymphoma, not otherwise specified (PTCL-NOS),
while two (6 %) were diagnosed with subcutaneous
panniculitis-like T cell lymphoma (SCPTCL), three (8 %)
with angioimmunoblastic T cell lymphoma (AILT), and
three (8 %) with nasal NK/T cell lymphoma (NKTCL). In
the non-LAHS group, 64 (52 %) patients were diagnosed
with PTCL-NOS, five (4 %) with SCPTCL, 18 (15 %) with
AILT, eight (7 %) with anaplastic large cell lymphoma
(ALCL), four (3 %) with enteropathic-type T cell lympho-
ma, and 24 (20 %) with NKTCL. The demographical and
clinical characteristics of the patients are listed in Table 2. In
the LAHS group the median age was 48 years (range, 16–
78 years) and 46 years (range, 10–77 years) in the non-
LAHS group. All of the patients with LAHS had B symp-
toms. Most of them were classified into the Ann Arbor III/
IV stage with hepatosplenomegaly and cytopenia. Fifty-six
percent (20/36) of the LAHS patients showed combined
BMI, which was higher than the BMI in patients without
LAHS (28 %, 34/123).
Laboratory findings are listed in Table 3. The elevated
rates of β2-MG, ferritin, fasting triglycerides, prothrombin
time, and CA125 levels were higher in the LAHS group
than in the non-LAHS group (P<0.05), so were hypofibri-
nogenemia (P<0.05) and liver dysfunction (P<0.05). In
contrast, the increased levels of LDH, IG, and renal dys-
functions were not significantly different between the LAHS
and the non-LAHS group.
Therapeutic results and survival analysis
With the median follow-up of 11 months (range, 1–
79 months), the overall OS rate of the 159 patients was
36 %. Statistically significant differences of the OS rates
were observed between the LAHS (11 %) and non-LAHS
(44 %) group (log-rank P<0.001; Fig. 1). The median
survival times of the two groups were 3 and 16 months,
respectively. Moreover, we compared the OS rates of PTCL-
NOS patients with and without LAHS and noted a signifi-
cant difference (log-rank P<0.001; Fig. 2). In the LAHS
group, statistically significant OS rate differences were not
observed comparing elevated IG and normal IG levels (log-
rank P 00.504; Fig. 3). The OS rate of LAHS patients
treated with a CHOP regimen (12 %) was lower than the
one of patients treated with an intensive chemotherapy
(21 %), but the difference was not statistically significant
(log-rank P00.545; Fig. 4). In our study, three LAHS
Table 2 Demographics and clinical characteristics of the PTCL:






Median age (years) 48 46
Range 16–78 10–77
Male/female 23/13 86/37
III/IV stage 34 (94 %) 93 (76 %) 0.013
IPI
0–1 4 (11 %) 30 (24 %) 0.087
2–3 22 (61 %) 79 (64 %) 0.733
4–5 10 (28 %) 14 (11 %) 0.694
B symptoms 36 (100 %) 94 (76 %) 0.001
Fever 33 (92 %) 51 (42 %) <0.001
Hepatosplenomegaly 26 (72 %) 28 (23 %) <0.001
Cytopenia for at least
two cell linesa
28 (78 %) 16 (13 %) <0.001
With BMI 20 (56 %) 34 (28 %) 0.002
PTCL-NOS 28 (78 %) 64 (52 %)
SCPTCL 2 (6 %) 5 (4 %)
AILT 3 (8 %) 18 (15 %)
NKTCL 3 (8 %) 24 (20 %)
ETTL 0 4 (3 %)
ALCL 0 4 (3 %)
B symptoms fever, night sweats, or weight loss, IPI international
prognostic index, BMI bone marrow involvement, PTCL-NOS periph-
eral T cell lymphoma, not otherwise specified, SCPTCL subcutaneous
panniculitis-like T cell lymphoma, AILT angioimmunoblastic T cell
lymphoma, NKTCL nasal NK/T cell lymphoma, ETTL enteropathic
type T cell lymphoma, ALCL anaplastic large cell lymphoma
a Cytopenia for at least two cell lines with hemoglobin <90 g/L (or
below 120 g/L for more than 4 weeks), platelet <10.0× 109 /L, and
neutrophils <1.0 ×109 /L
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patients were in critical conditions with high fever, hepatosple-
nomegaly, severe liver dysfunctions, and cytopenia and were
given one to three times of plasma exchange before they
received chemotherapies. The results showed that the median
survival time of these three patients was 5 months, which was
longer than that of all other LAHS patients. In summary, LAHS
led to worse outcomes not only for all PTCL-affected but also
for the PTCL-NOS-affected patients and elevated IG levels
were not a significant prognostic factor for LAHS patients.
Discussion
HLH is a potentially fatal hyperinflammatory condition
caused by a highly stimulated but ineffective immune re-
sponse [14]. Acquired HLH is associated with malignant
diseases, especially lymphomas (LAHS) [6, 15] and most
cases of LAHS are associated with T cell or natural killer
(NK)/T cell lymphoma, while LAHS secondary to B cell




LDH >225 U/L 22/36 (61 %) 64/123 (50 %) 0.336
β2-MG >2,200 μg/L 27/36 (75 %) 50/123 (41 %) <0.001
CA125 >35 U/mL 23/28 (82 %) 49/96 (51 %) 0.003
Ferritin ≥500 μg/L 21/25 (84 %) 15/102 (15 %) <0.001
Fasting triglycerides
>3 mmol/L
24/32 (75 %) 15/93 (16 %) 0.015
Prothrombin time >14 s 13/29 (45 %) 18/77 (23 %) 0.03
Fibrinogen <1.5 g/L 24/34 (71 %) 8/96 (8 %) <0.001
Liver dysfunctiona 30/36 (83 %) 44/121 (36 %) <0.001
Renal dysfunctionb 6/36 (17 %) 12/121 (10 %) 0.264
IG elevation for at
least one typec
9/21 (43 %) 34/90 (38 %) 0.220
LDH lactate dehydrogenase, β2-MG β2-microglobulin, IG
immunoglobulin
a The criteria for liver dysfunction is jaundice, total bilirubin >17.1
umol/L, serum albumin <35 g/L, alanine aminotransferase, and/or
aspartate aminotransferase >40 U/L
b The criteria for liver dysfunction is creatinine >133 umol/L and/or
blood urea nitrogen >8.2 mmol/L
c The criteria for IG elevation is IgG >16 g/L, IgA >4 g/L, and IgM
>2.3 g/L
Fig. 1 Kaplan-Meier estimates for the OS rates of 36 PTCL patients
with LAHS compared to 123 PTCL patients without LAHS. A statis-
tically significant difference was observed between the two groups
(LAHS (11 %) and non-LAHS (44 %)), p<0.001
Fig. 2 Kaplan-Meier estimates for the OS rates of 28 PTCL-NOS
patients with LAHS compared with 64 PTCL-NOS patients without
LAHS. A statistically significant difference was observed between the
groups PTCL-NOS patients with LAHS (7 %) and PTCL-NOS patients
without LAHS (41 %), p<0.001
Fig. 3 Kaplan-Meier estimates for the OS rates of LAHS patients with
elevated immunoglobulin (IG) levels at initial diagnosis compared to
patients with normal IG levels. There was no statistically significant
difference between the groups (P00.504)
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lymphomas are quite rare [15–19]. The frequency of LAHS
varies greatly among different clinicopathological entities of
PTCLs. Kobayashi et al. [19] reported in pediatric patients
from Asia an incidence of 23 % from 22 PTCL patients with
LAHS at initial diagnosis and the frequency of HLH was
33 % (3/9) in PTCL-NOS, followed by 20 % (2/10) in nasal
NK/T cell lymphoma. Our data revealed 23 % of 159 PTCL
patients with LAHS at initial diagnosis and the frequency of
HLH was up to 30 % (28/92) in the PTCL-NOS group, 29 %
(2/7) in the SCPTCL group, 14 % (3/21) in the AILT group,
and 11 % (3/27) in the NKTCL group. In our study, the
proportion of LAHS in the PTCL and PTCL-NOS groups
was corresponding to Kobayashi's report [19], except that
the frequency of HLH in the NKTCL group was lower.
Because the number of pediatric patients is small in the
literature, further research needs to be done.
We noted that in addition to β2-MG, ferritin and triglyc-
eride increased more remarkably in the LAHS group than in
the group without LAHS, which suggested a poor prognosis
and further confirmed their importance as indicators for
evaluating a T cell lymphoma prognosis. In contrast, renal
dysfunction, increased levels of LDH and IG were irrelevant
to whether LAHS was complicated or not. In our study,
56 % of the 36 patients had BMI and 72 % of the 36 patients
had hepatosplenomegaly. The percentages in the LAHS
group were clearly higher than that in the non-LAHS group
(56 vs. 28 %, P00.002; 72 vs. 23 %, P<0.001, respective-
ly), which indicates that early BMI and hepatosplenomegaly
are prominent features in T cell lymphomas with LAHS.
Moreover, we detected peripheral lymphadenopathy only in
47 % of the 36 patients with LAHS. It is difficult to
diagnose the disease accurately at an early stage without
enlargement of superficial lymph nodes. Consequently, re-
peated biopsies of bone marrow from different locations are
necessary and may increase the detection rates.
Unlike cytopenia and liver dysfunction being often men-
tioned, renal failure in LAHS patients was observed rarely.
Renal failure was reported to occur at the advanced stages of
HLH and is related to abnormally high concentrations of
nephrotoxic IL-6 in the blood serum [20]. In our study, we
found renal failures in 17 and 10 % (P00.264) of the PTCLs
patients with and without LAHS, respectively. All of them
were classified into Ann Arbor III/IV stages. Though the
difference was not statistically significant, we need to be
vigilant of creatinine and blood urea nitrogen elevation for
early detection of renal failures.
CA125 has been widely used as a tumor marker in
monitoring epithelial ovarian cancer. In aggressive NHL,
CA125 was found to correlate with stage, tumor bulk,
involvement of more than one extra-nodal site, and presence
of effusion. Elevated levels of CA125 were found to predict
decreased survival and also highly related to high levels of
LDH and β2-MG [21–23]. Contrary to other serum markers
such as β2-MG and LDH, CA125 apparently is not released
by lymphoma cells and might be secreted by mesothelial
cells stimulated via lymphokines derived from NHL [24].
Our data showed that the serum CA125 level increased in
82 % of the patients with LAHS and in 51 % of the patients
without LAHS (P00.003). As it increased in 45 % of the
total aggressive T cell lymphoma patients, we believe that
the determination of the serum CA125 level is useful in
predicting poor T cell lymphoma prognoses.
Combination chemotherapy remains the main treatment for
Tcell lymphoma associated with LAHS. Our data showed that
17 patients received a CHOP regimen as initial therapy, while
some other regimens such as ECHOP, CHOP+Ara-C, DHAP,
hyper CVAD, MINE, and ESHAP were employed in 19
patients. The estimated OS rates of LAHS patients treated
with a CHOP regimen (12 %) was lower than that of patients
with intensive chemotherapy (21 %), but the difference was
not statistically significant (log-rank P00.545). The possible
explanation for this is that LAHS is usually accompanied by
multiorgan and especially cardiac dysfunctions, and intensive
chemotherapy might further aggravate organ damage, thereby
affecting the survival time. Because intensive chemotherapy is
more bone marrow- and immune-suppressive, the toxicity of
chemotherapy agents should be considered when patients
accept intensive chemotherapies.
The mechanism of LAHS is generally believed to be
related to a cytokine storm [25], and based on this theory,
some researchers reported that plasmapheresis could
achieve good therapeutic outcomes in secondary HLH [26,
27]. Yanagiya et al. [28] noted that a patient with diffuse
large B cell lymphoma-associated HLH had his TNF-a, IL-
Fig. 4 Kaplan-Meier estimates for the OS rates of LAHS patients with
intensive chemotherapy compared to those with a CHOP regimen.
There was no statistically significant difference between the two
groups (P00.545)
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6, and IL-8 serum levels reduced to normal values after
plasmapheresis. In our study, three LAHS patients who were
given one to three times of plasma exchange before they
received chemotherapies had longer survival times. However,
like in our retrospective analysis, most of the related reports by
now are limited to single cases, and thus more studies are
needed to further investigate the efficacy of plasmapheresis.
In conclusion, PTCL patients with LAHS had poorer
prognoses than those without and the therapeutic outcome
was unsatisfactory. Awareness of the clinical symptoms such
as fever, hepatosplenomegaly, cytopenia, and constantly in-
creasing levels of serum β2-MG, ferritin, CA125, and tri-
glyceride is crucial in order to diagnose LAHS early and start
life-saving therapies on time. Repeated biopsies of multiple
bone marrows from different locations in those without
enlargement of superficial lymph nodes are advisable in
order to improve the diagnosis. Plasmapheresis as initial
therapy is worth trying if the overall outcome of other treat-
ments is unsatisfactory. In general, the treatment of LAHS
remains a challenge and an intensive chemotherapy did not
led to obvious advantages for the OS rate than a CHOP
regimen due to its severe toxicity. Because of the present
unsatisfactory therapeutic outcomes, well-designed clinical
studies are required to improve the therapeutic procedures.
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